ArticlePloS one2024

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.

R J S D Heine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.